GIAPREZA® (angiotensin II) in Vasodilatory Shock
Maggiano's Little Italy
7875 Montgomery Road
Cincinnati, OH 45236
Tuesday, October 14, 2025 at 6:00pm ET - 8:00pm ET
Add this event to your calendar
Info
Topic
INNOVIVA Specialty Therapeutics
Additional Information
GIAPREZA® (angiotensin II) in Vasodilatory Shock
by Innoviva Specialty Therapeutics
Innoviva Specialty Therapeutics develops and delivers innovative therapies for patients in critical care and infectious disease.
- Critical Care: Innovative solutions for patients with serious, life-threatening conditions.
- Infectious Diseases: Therapies for emerging illnesses caused by drug-resistant microorganisms.
- Global Mission: Advancing solutions for the most critical and urgent infections identified by the world's leading public health organizations.
Speakers
Senior Director
Innoviva Specialty Therapeutics.
Dr. Chuck Greenfeld, PhD, is Senior Director Medical Science Liaison and Medical Affairs Field Team Lead at Innoviva Specialty Therapeutics. He has been with the company since 2017, joining prior to the approval of Giapreza (angiotensin II) in late 2017 and its subsequent launch in early 2018. He obtained his PhD in Physiology in 2006 from the University of Maryland, Baltimore, after which he completed a postdoctoral fellowship at Johns Hopkins University. He has been in industry since 2008, having begun his career at Questcor Pharmaceuticals and later working at ZS Pharma/AstraZeneca, and OPKO Renal. In his current role he supports educational and research initiatives related to Giapreza, as well as Innoviva Specialty Therapeutics’ infectious disease portfolio.